

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1595494> since 2017-01-11T16:49:24Z

Published version:

DOI:10.1016/j.jtho.2016.01.004

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Righi, Luisella; Vatrano, Simona; Di Nicolantonio, Federica; Massa, Federica; Rossi, Giulio; Cavazza, Alberto; Volante, Marco; Votta, Arianna; Izzo, Stefania; Iacono, Marco Lo; Ardisson, Francesco; Di Maio, Massimo; Novello, Silvia; Scagliotti, Giorgio Vittorio; Papotti, Mauro. Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung. *JOURNAL OF THORACIC ONCOLOGY*. 11 (4) pp: 504-515.
DOI: 10.1016/j.jtho.2016.01.004

The publisher's version is available at:

<http://linkinghub.elsevier.com/retrieve/pii/S1556086416002872>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Retrospective multicentre study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung

Luisella Righi, MD¹, Simona Vatrano, BSc¹, Federica Di Nicolantonio, PhD^{1,2}, Federica Massa, MD¹, Giulio Rossi, MD³, Alberto Cavazza, MD⁴, Marco Volante, MD¹, Arianna Votta, MLT¹, Stefania Izzo, MLT¹, Marco Lo Iacono, BSc¹, Francesco Ardisson, MD¹, Massimo Di Maio, MD¹, Silvia Novello, MD¹, Giorgio Vittorio Scagliotti, MD¹ and Mauro Papotti, MD^{1,5}

*Department of Oncology, University of Torino at San Luigi Hospital, Orbassano (Torino); ²Candiolo Cancer Institute-FPO, IRCCS, SP 142 km 3.95, Candiolo (Torino), Italy; ³Pathology Unit, University of Modena, Modena; ⁴Pathology Unit, Department of Oncology and Advanced Technologies, Azienda Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia; ⁵Pathology Unit, City of Health and Science, Torino, Italy.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Correspondence to:

Giorgio Vittorio Scagliotti,

University of Torino, Department of Oncology at S. Luigi Hospital

Regione Gonzole, 10

10043 Orbassano (Torino), Italy

Phone +390119026414

Fax +390119015184

Email: giorgio.scagliotti@unito.it

Short title: NGS in mucinous lung adenocarcinoma

1
2 **Conflict of interest and source funding:** work partially supported by grants from the “Fondazione
3 Guido Berlucci”, Brescia (approved April 24, 2013) to MP and HEALTH-F2- 2010-258677-
4
5 CURELUNG from the European Community’s Seventh Framework Program (FP7/2007-2013) to
6
7
8
9
10 GVS.

11
12 M.P.: honoraria from Eli Lilly, Novartis, Pfizer, Clovis Oncology; G.V.S.: honoraria from Eli Lilly,
13
14 Astra Zeneca, Pfizer, Roche, Clovis Oncology; S.N.: honoraria from Eli Lilly, Boehringer Ingelheim,
15
16
17 Roche, Astra Zeneca, MSD. The other authors have no conflicts of interest to declare.
18
19

20
21 SV is a PhD fellow at the University of Turin, Doctorate School of Biomedical Sciences and
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

ABSTRACT

1
2 Mucin-rich lung adenocarcinomas (ADC), namely mucinous and colloid ADC, are classified as ADC
3
4 variants according to the WHO 2015 classification. A correlation between morphological patterns
5
6 and mutational status of these rare entities is not well established. We investigated the mutational
7
8 profile of mucin-rich lung ADC in correlation with histopathologic and morphological features with
9
10 the goal of identifying biological tumor characteristics of potential prognostic and therapeutic
11
12 interest. A series of 54 surgically resected primary mucinous lung ADC samples was retrospectively
13
14 analyzed for clinical-pathological characteristics and by targeted Next-Generation Sequencing.
15
16 Fifty cases were invasive mucinous (IMA, 32 pure and 18 mixed) and 4 were colloid predominant
17
18 ADC (CPA). IMA cases with pure mucinous pattern were associated to a lower risk of vascular
19
20 invasion (p=0.01), absence of signet ring cell (p=0.03), negative nodal status (p=0.006) and early
21
22 clinical stage (p=0.02). The most prevalent mutations involved *KRAS* and *TP53* genes. The majority
23
24 of mutations clustered in the MAP-AKT kinase (*KRAS*, *PIK3CA*, *STK11*, *PTEN*, *AKT1*, *HRAS*, *BRAF*) and
25
26 the p53/DNA repair (*TP53*, *CDKN2A*, *ATM*, *RB1*) pathways. A few uncommon *EGFR* mutations were
27
28 found. A correlation between a higher number of mutations and favorable clinical outcome was
29
30 seen (p<0.001). Our data showed that mucinous ADCs have peculiar pathological and molecular
31
32 features that might imply a differentially tailored therapeutic approach compared to conventional
33
34 lung ADC.
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **KEY WORDS:** lung, mucinous adenocarcinoma, next generation sequencing, mutation
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

INTRODUCTION

1
2 Mucinous lung adenocarcinomas (ADC) account for 2-10% of all lung ADCs. Based on a proposal
3
4 from the International Association for the Study on Lung Cancer¹, the WHO has recently classified
5
6 lung ADCs according to their invasive capacity, predominant architectural pattern and amount of
7
8 mucin production². Specifically, a distinction between invasive ADC of conventional type and its
9
10 variants, which include invasive mucinous ADC (IMA) and colloid ADC, was made. An alternative
11
12 classification of lung ADCs classifies these tumors into terminal-respiratory-unit (TRU) and non-
13
14 TRU types on the basis of distinct morphological features^{3,4}. Lung mucinous ADCs belong mostly to
15
16 the non-TRU type group, as they originate from the bronchial epithelium or submucosal glands,
17
18 and exhibit a gastric-mucin phenotype and a poorer prognosis than TRU type ADCs⁵.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Despite these efforts of re-classification, mucinous ADCs present a heterogeneous spectrum of morphological patterns^{6,7} and, potentially, a high degree of molecular heterogeneity could drive the observed histological differences, but few studies have specifically addressed this hypothesis. Indeed, while the prevalence and type of “druggable” molecular alterations in conventional ADC have been well characterized⁸, scant information is available about invasive mucinous ADC variants. Most of the available studies that included all types of ADC and employed low sensitive and *single-gene* technologies, have established that *KRAS* mutations occur in 61% and 15% of invasive mucinous and colloid ADCs, respectively^{9,10} and are associated with poor prognosis and lack of response to chemotherapy¹¹. *KRAS* mutations have been reported to often co-occur with *CDKN2A/B* inactivation and low expression of the Thyroid Transcription Factor 1 (TTF1)¹², although the clinical implications of these findings remain to be fully elucidated¹³. A recent study has identified a *CD74-NRG1* gene fusion as a novel driver in the carcinogenesis of invasive mucinous ADC. However, these fusions present at a low prevalence (<10%) and are confined to *KRAS* wild-type cases¹⁴. More recently, Shim and colleagues have performed targeted NGS for gene fusions

1
2
3 and mutations in 30 mucinous ADC samples previously found to be *KRAS* wild-type by Sanger
4 sequencing. They described a large number of gene fusions, unexpectedly infrequent *TP53*
5 mutations and an overall low number of mutations, without significant differences in terms of age,
6
7 gender, smoking status and stage compared to *KRAS* mutated cases¹⁵.
8

9
10 Based on the lack of complete and unanimous information on the clinical-pathological and
11
12 molecular characteristics of pulmonary mucin-rich ADC, we retrospectively performed a detailed
13
14 morphological analysis of mucinous characteristics and targeted Next-Generation Sequencing (T-
15
16 NGS) of 50 genes in 54 resected mucinous ADC samples (irrespective of their *KRAS* genotype) in
17
18 order to investigate genotype-phenotype relationships and identify molecular alterations of
19
20 potential prognostic and therapeutic interest.
21
22
23
24
25
26
27

28 **MATERIALS AND METHODS**

29
30 **Patients and tissue samples** – A consecutive series of surgically resected primary invasive lung
31
32 ADC with mucinous features, diagnosed in Caucasian patients from April 2003 to December 2013,
33
34 was retrospectively collected at three Institutions (San Luigi Hospital, Orbassano, Torino;
35
36 Policlinico Hospital, Modena; Santa Maria Nuova Hospital, Reggio Emilia). All cases were centrally
37
38 reviewed by three pathologists (LR, MP and GR) according to the 2015 WHO lung adenocarcinoma
39
40 classification². Study inclusion criteria were the presence of a mucinous pattern (i.e. IMA and
41
42 colloid ADC, while enteric ADC cases were excluded), the lack of a prior non-lung related cancer
43
44 diagnosis, the presence of accurate clinical follow-up data, as well as the availability of residual
45
46 tissue for genetic analyses. Patients were staged according to the American Joint Committee on
47
48 Cancer TNM Staging Manual¹⁶. The Institutional Review Board approved the study. All samples
49
50 were de-identified and cases anonymized by a pathology staff member not involved in the study.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Clinical parameters were compared and analyzed through coded data.

1
2
3 **Morphological analysis** - Hematoxylin-eosin stained slides of each tumor were reviewed. The
4
5 following histological parameters were assessed (Figure 1): a) the presence of a non-mucinous
6
7 component, that segregated the IMA group into *pure* (mucinous features $\geq 90\%$) or *mixed*; in the
8
9 mixed cases the predominant pattern of conventional ADC was also recorded; b) the presence of
10
11 *extracellular mucin* that was recorded when observed in $\geq 10\%$ of the tumor; c) the extent of *tufts*
12
13 (bunches or small clusters of neoplastic mucinous cells attached to the alveolar wall, closely at the
14
15 base and loose at the upper ends) scored as percentage (using a cut-off $\geq 10\%$ to define the
16
17 presence or absence of tufts); d) the presence of $\geq 5\%$ of signet ring cells (SRC) component,
18
19 characterized by cells with large intracellular mucin drops and peripheral nuclei displaced toward
20
21 one end of the cytoplasm.
22
23
24
25
26
27
28
29
30

31 **Immunohistochemistry** - Formalin fixed paraffin embedded (FFPE) tumor tissue block and
32
33 standard automated immunostainer (BenchMark, Ventana Medical System, Tucson, USA) were
34
35 used. Specific primary antibodies against TTF1 (8G7G3/1, Dako/Agilent, Glostrup, Denmark), CDX2
36
37 (DAK-CDX2, Dako), cytokeratin 7 (CK7, OV-TL 12/30, Dako), cytokeratin 20 (CK20, KS20.8,
38
39 Neomarkers, Fremont, USA), p53 (DO-7, Neomarkers), ALK (D5F3, Roche-Ventana), c-
40
41 erbB2/HER2/neu (HER2, SP3, Neomarkers) were used. Staining patterns were nuclear for TTF1 and
42
43 CDX2 (scored positive even in the presence of a weak reactivity) and for p53 (in which a
44
45 percentage higher than 5% of stained cells was considered positive); cytoplasmic for CK7 and
46
47 CK20, and membranous for HER2. ALK was scored positive in the presence of granular cytoplasmic
48
49 staining and positive cases were confirmed by FISH analysis using the FISH break apart probe from
50
51 Vysis (Abbott Laboratories, Abbott Park, Illinois USA), as recommended¹⁷.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Genomic DNA extraction, Targeted Next-Generation Sequencing and Variant Caller and

Annotation - Genomic DNA (gDNA) was obtained from FFPE tissues after manual micro-dissection (in mixed IMA cases, the mucinous component was selectively micro-dissected) with enrichment for neoplastic cellularity (at least 50% tumor cells), as previously reported¹⁸. T-NGS analyses were performed in 54 samples using the Ion Torrent Personal Genome Machine (PGM, Life Technologies, Grand Island, USA) and the 50-gene Ion Ampliseq Cancer Hotspot Panel v2 (Life Technologies), as previously reported¹⁸. This panel includes genes known to play a prominent role in carcinogenesis across several malignancies and/or that can be therapeutically viable (Supplementary Table S1). Alignment to hg19 human reference genome and Variant Calling included in Torrent Suite Software 4.0 was used to identify variations in target regions¹⁸. Target regions for mutational analysis and RefSeq sequences used for gene annotations are detailed in Supplementary Table S1. All genome coordinates are human genome build GRCh37/hg19.

Bioinformatics pipeline and experimental validation - A custom-designed bioinformatics pipeline, as illustrated in Supplementary Figure 1, was used to analyze genetic variants. To minimize the risk of calling alterations derived from sequencing errors or PCR-based enrichment artifacts, all reads with a QC<30 were excluded from further analyses. The genetic alterations were further annotated using the following databases: COSMIC (version 70), the Single Nucleotide Polymorphism (dbSNPs build 137), the 1000 Genomes Project (1000G), the 6500 exomes of the National Heart, Lung and Blood Institute Exome Sequencing Project and the Non-synonymous SNPs' Functional Predictions (dbNSFP light version 1.3). *In silico* analyses were carried out to predict both the amino acid changes potentially deleterious on protein function and clinical implications of genetic alterations not previously identified by means of SIFT (Sorting Intolerant From Tolerant) and PolyPhen-2 (Polymorphism Phenotyping) algorithms. Matched germ-line DNA

1 samples were not available for parallel sequencing analysis. Established tools can accurately call
2 somatic variants when matched normal and tumor samples are sequenced, but no gold standard
3 method is currently available in the absence of matching germ-line DNA data. Therefore, the
4 discrimination of likely germ-line or likely somatic variants was performed based on arbitrary
5 criteria. Known polymorphisms recorded in the above mentioned public polymorphisms databases
6 were removed from the analysis¹⁹. We then applied a stringent minimum variant read frequency
7 cutoff of 15% for all candidate alterations different from well-characterized known hotspots²⁰.
8 Lastly, we labeled single-nucleotide variants of likely germ-line origin those variants that followed
9 the Hardy-Weimberg equilibrium and displayed an allelic frequency either in the 45%-55% range
10 or nearly 100%. Whereas we considered likely somatic alterations those variants whose allelic
11 frequency violated the Hardy-Weimberg equilibrium, as previously described²¹. When feasible,
12 sequence variant confirmation of mutations was performed by conventional wet techniques
13 including pyro-sequencing or Sanger sequencing, allele-specific PCR and Real-Time PCR, as
14 previously described²².

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 **Statistical analyses** - Chi-square or Fisher's exact test, as appropriate, were used to test the
39 association between mutations and clinical - histological variables. Cohen coefficient was used to
40 evaluate concordance between different tests. For statistical purposes patients were segregated
41 into groups based on the following criteria: a) presence of high or low number of likely somatic
42 non-synonymous mutations was defined by employing as a cut-off the statistical median value of
43 the dataset; b) overall wild type or mutated status, based on the presence of at least one mutation
44 in any given gene. Patients without evidence of progressive disease at the analysis were
45 considered censored at the time of the last follow-up. Median follow-up time was 61 months
46 (range 41-84). Median overall survival (OS) was defined as the time from diagnosis to death for
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 disease or to date of the last follow up. Univariate analyses of survival were performed with
2 Kaplan-Meier curves and the significance verified by log-rank test. In order to test the prognostic
3 role of the number of mutations (and of other clinical-pathological variables) adjusted by stage,
4 multivariate analyses were performed applying a Cox proportional hazards model. All analyses
5 were performed using GraphPad software or the website <http://statpages.org/prophaz.html>.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Multivariate analyses were performed using S-Plus (S-PLUS 6.0 Professional, release 1; Insightful Corporation, Seattle, WA, USA). *P* values of ≤ 0.05 were considered statistically significant.

RESULTS

Tissue samples and clinical-pathological data - Fifty-four cases of resected mucinous ADC (50 IMA, 32 pure and 18 mixed and 4 colloid predominant, CPA) were analyzed (Orbassano n=35; Modena n=21; Reggio Emilia n=15) (Table 1). Neither mucinous AIS nor MIA cases were found. Two patients had synchronous nodules: one patient had two different bilateral mucinous ADC nodes, while the other had two separate nodes (a mucinous ADC and a conventional acinar ADC) in the same lobe. No significant morphological differences were found between IMA and CPA, with the exception of extracellular mucin ($p=0.03$) and CDX2 expression ($p=0.02$) that were more represented in CPA, as expected. Conversely, in the mixed IMA subgroup, a higher prevalence of vascular invasion ($p=0.01$), predominant invasive growth pattern ($p<0.0001$), signet ring cells (SRC) ($p=0.02$), lymph node involvement ($p=0.006$) and higher stage ($p=0.03$) was found. The presence of tuft growth was significantly associated with the lack of SRC component ($p=0.04$), without correlation with any subtype.

The immunohistochemistry profile was characterized by a heterogeneous, not mutually exclusive expression of CK7 (100%) and CK20 (48%), TTF1 (48%) and CDX2 (13%). p53 was expressed in 24/54 (44%) cases, ranging from 5% to 40% of positive cells. All cases were negative for HER2,

1 while two (4%) mixed IMA samples were positive for ALK rearrangement in the SRC component,
2
3 (confirmed also by FISH, see materials and method section).
4
5
6

7 **T-NGS of mucinous adenocarcinoma** - An adequate library was obtained in all but two of the 54
8
9 primary tumor samples analyzed by T-NGS. After read quality filtering, mapping and alignment to
10
11 reference genome (hg19), the median sequencing depth resulted 348x. A total of 837 genetic
12
13 variations (median=16, range 1-39) were identified either in exonic (namely non-sense,
14
15 synonymous, non synonymous likely-germinal and non synonymous likely-somatic alterations) or
16
17 regulatory regions (Figure 2A). The predominant nucleotide changes were C:G→T:A transitions,
18
19 consistent with previous ADC genomics data⁸, with no significant difference among individual
20
21 genes (Figure 2B).
22
23
24
25
26

27
28 We elected to focus on 281 mutations leading to a protein change (i.e. non synonymous and
29
30 nonsense mutations), as these are more likely to play a causative role in tumorigenesis and
31
32 represent therapeutic vulnerabilities. As detailed in the Methods, we further categorized all non-
33
34 synonymous variants into likely somatic (e.g. tumor-specific) or likely germ-line based on prior
35
36 annotation in public polymorphism databases and their allelic frequency (Supplementary Tables S2
37
38 and S3). The number of non-synonymous mutations considered to be tumor-specific was 190
39
40 (median=2 per sample, range from 1 to 18). These variants were distributed across 26 different
41
42 genes and were found in 43 samples (83% with at least one mutation) (Figure 3). Nine cases (17%)
43
44 – which were named “all wild-type” – did not harbor any likely somatic mutations in the set of
45
46 sequenced genes, although one of these cases presented an ALK rearrangement by FISH analysis.
47
48 Somatic mutated genes clustered mainly in four signaling pathways with the highest
49
50 prevalence of mutations in the MAP kinase (41%), tyrosine kinase (23%) and DNA repair (22%)
51
52 pathways.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

KRAS was the most commonly mutated gene and mutations were observed in 37/52 (71%) samples. Near all mutations affected glycine at position 12 and were confirmed by pyrosequencing. *TP53* was the second most mutated gene (24/52, 46%), mainly with missense or InDel changes with a consequent loss of protein function. In four cases, non-sense mutations with a premature stop-codon expected to down-regulate protein levels was detected. All *TP53* mutations were validated by Sanger sequencing.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Six out of the seven *EGFR* single nucleotide variants were of uncertain biological and/or therapeutic relevance (G721S, E746K, D761N, V765M, R776C, A871T). However, a *de novo* T790M mutation, known to confer resistance to tyrosine kinase inhibitors, was detected in one sample. We found likely-somatic mutations of *PIK3CA* in seven tumors, most of which are known to be oncogenic (2 cases with E542K, 1 Q546H, 1 A1020V, 1 M1043I, 1 G1049S) and could have implications for targeted therapy. Two samples harbored the R132H hotspot mutation in *IDH1* that has been found to drive tumorigenesis in glioblastoma and certain hematological malignancies and for which clinical inhibitors are being developed²³. We also detected one case carrying a *PDGFRA* variant of unknown function but affecting the tyrosine kinase domain (G668S), as well as *KIT* mutations in six tumors (2 V530I, 2 L576F, 2 P577S) of uncertain functional relevance and not previously associated with clinical response to targeted therapy.

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

TP53/p53 genotype/phenotype analysis - Immunohistochemistry for p53 was performed as a surrogate of validation of the *TP53* mutational status, since a strong positive nuclear staining is considered to be the phenotypic counterpart of genetic alterations²⁴. In our series, p53 was expressed in 24/52 cases (46%) with variable intensity and a heterogeneous pattern of distribution in tumor areas ranging from 5 to 40% of positive cells, while in 28/52 cases (54%) resulted completely negative or with few focal positive tumor cells. The observed intra-tumoral

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

heterogeneity of p53 immunostaining may implicate that *TP53* mutations could be present in a fraction of tumor cells. To test this hypothesis, we assessed the predicted functional relevance of all *TP53* gene mutations occurring at an allelic frequency of at least 5%, indicating their possible subclonal origin. Overall, among p53 positive cases, 17 harbored missense mutations and 7 were WT in the sequenced regions. On the other hand in the p53 negative group, 5 cases harbored dominant negative mutations, 4 showed nonsense mutations and 19 cases were wild-type or with not-functional variants. A significant correlation ($p= 0.002$) and a moderate concordance (Cohen coefficient k value= 0.53) between the two tests were thus observed (Supplementary Figure 2).

Molecular to clinical-pathological correlations - Correlative analyses between molecular data and clinical-pathologic variables are summarized in Supplementary Table S4. Tuft growth was the only feature significantly associated with a higher somatic non-synonymous number of mutations ($p=0.01$). Notably, tuft growth was found in 27/42 samples displaying at least one mutation in any gene ($p=0.0002$) and none of the cases that were found to be 'all wild-type' displayed tuft growth. Rather, these samples lacking mutations presented with a higher pathological stage (67%) and all were IMA (100%), more frequently of the mixed subtype (67%). They also had lesser vascular invasion (78%) and TTF1 positivity (78%). Interestingly, cases with at least one mutation in any gene were most commonly associated with a lack of TTF1 expression (25/43, 58%). The same immunohistochemical pattern was also detected in *KRAS* mutated cases (21/37, 57%), even if the association was not statistically significant (Supplementary Table S4). Furthermore, *KRAS* mutated cases were associated with a low pathological stage (57%), absence of lymph node involvement (95%), low SRC component (89%), presence of tuft growth (68%) and absence of p53 protein expression (68%) (Supplementary Table S4).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Survival analyses - At univariate analysis smoking status ($p=0.03$), pathological higher stage ($p=0.0006$), mixed IMA subtype ($p=0.03$), predominant invasive growth pattern ($p=0.02$), vascular invasion ($p=0.005$), and presence of SRC ($p=0.05$) were predictive of poor survival, together with *KRAS* and *TP53* wild type status. Since the median number of non-synonymous likely somatic alterations was 1, this was chosen as an arbitrary cut-off value to divide patients in two categories based on the number of mutations. The subset of patients displaying more than one somatic non-synonymous mutations in their tumors ($N= 29$) had a significantly better overall survival (median overall survival not reached) compared to cases showing 0-1 mutations (34 months, HR 0.21, 95% CI 0.08 to 0.54, $p<0.001$, Figure 4). When the prognostic role of the number of mutations was tested in a multivariate analysis including stage of disease, number of mutations remained independently predictive of overall survival (HR 0.37, 95% CI 0.14 – 0.99, $p=0.048$).

DISCUSSION

Mucinous lung ADCs have been associated with poor recurrence-free survival and adverse prognosis, as the disease often presents with minimal or misleading clinical symptoms and multifocal heterogeneous unresectable lesions^{25,26}. In this study, we explored the pathological characteristics and the genetic profile of 54 mucin-rich ADC of the lung with the aim of unveiling genotype-phenotype relations and identifying clinically valuable markers.

No significantly different clinical-pathological features or survival outcome were found between IMA and CPA subgroups with the exception of the presence (by definition) of extracellular mucin in 100% of CPA ($p=0.03$). Compared to conventional ADC, lung IMAs are associated with a worse prognosis²⁷ and are less sensitive to chemotherapy²⁸. In the present study, we failed to demonstrate significant differences in overall survival between IMA and CPA because of the extremely limited number of the latter, a very rare subtype¹⁰. On the other hand, the pure

1 mucinous IMA subgroup was significantly associated with better survival when compared to the
2 mixed one. Pure IMA samples presented favorable features such as the lepidic growth pattern, the
3
4 absence of vascular invasion, SRC component, and lymph node involvement, as well as
5
6
7 pathological stage I. In the absence of other high-grade morphological features, we could not
8
9 stratify the current series of mucinous ADC into prognostically relevant grading-based subgroups.

10
11
12 Our observations take into consideration the fact that lung mucinous ADCs were judged unsuitable
13
14 for inclusion in the recently proposed grading systems based on architectural and cytological
15
16 features^{29,30,31}. Nevertheless, the presence of tufts was distributed in all the histological categories
17
18 analyzed (either CPA, pure IMA or mixed IMA) at very high percentage (75%, 94%, 72%,
19
20 respectively), whereas the presence of signet ring cells occurred at low frequency, from 22% to
21
22 28% in our series, possibly suggesting that the tufts could be a specific hallmark of this tumor type.
23
24
25 Furthermore, tuft growth was also significantly associated with the presence of higher number of
26
27 somatic mutations, thus confirming –for such tumor type- the importance of this specific
28
29 cytomorphological feature, which is also detectable in small core biopsies³².

30
31
32 A limitation of this study is the lack of matched germ-line DNA, which has prevented us from
33
34 confirming the somatic nature of the genetic variants identified by T-NGS. However, we carefully
35
36 reviewed all variants taking into consideration both their allelic frequency and annotation in
37
38 polymorphism databases to minimize the risk of calling false-positive somatic mutations. This
39
40 analysis has retrieved a list of 190 likely somatic tumor-specific mutations, with a median value of
41
42 two mutations per sample, and *KRAS* mutations clearly dominated the mutational landscape of
43
44 mucinous ADC. *KRAS* is the most frequently mutated oncogene in male, smoker and non-Asian
45
46 lung ADC patients (5% to 40%) and associated to the mucinous ADC subtype with controversial
47
48 clinical relevance^{9,33,34}. Consistently with earlier reports, mutations were detected in 71% cases
49
50 (including 100% of CPA and 77% of IMAs)⁹. We found that *KRAS* mutations are significantly
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 associated with lymph node negativity, absence of SRC and presence of tufts. Furthermore, in our
2 series, the presence of KRAS mutations was associated with better overall survival at univariate
3 analysis (HR 0.31, 95%CI 0.12-0.79, p=0.009). However, as mentioned in the results, KRAS
4 mutations were significantly more common in stage I patients compared to patients with more
5 advanced disease. In the Cox model adjusted by stage of disease, KRAS mutation was not an
6 independent prognostic factor (HR 0.57, 95%CI 0.21-1.53, p=0.27).
7
8
9

10 *TP53* was the second most commonly altered gene with a prevalence of 46%. Specifically, we
11 detected several *TP53* mutations with a known dominant negative function and other less
12 common mutations of the truncating type, which are usually associated to absence of protein
13 expression. This finding could explain the relatively good concordance between p53
14 immunoreactivity and the *TP53* genetic status. Our results are apparently conflicting with those of
15 Shim and colleagues, who reported a significantly lower prevalence of *TP53* mutations¹⁵. A
16 potential explanation for this discrepancy could lie in the fact that they analyzed by NGS only
17 tumors known to be KRAS wild-type by Sanger sequencing, while we sequenced a larger cohort
18 that included all tumors irrespective of KRAS genotyping. Indeed, 18/24 *TP53* mutant cases also
19 harbored KRAS mutations. Other differences between these studies include the specific genes
20 and/or the exons sequenced in the respective panels (Supplementary Table S5); as well as patient
21 ethnic origin, since Shi et al., analyzed a cohort composed of both Caucasian and East Asian
22 patients and our study only included Caucasian individuals. Finally, differently from the cohort
23 analyzed by Shim and colleagues, in this study the majority of patients were smokers, and some of
24 the detected genetic alterations are more commonly reported in smoking-related tumors.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 None of the examined tumor samples showed positive immunostaining of HER2, a gene highly
55 expressed in mucinous KRAS wild type cases displaying the CD74-NRG1 fusion product^{14,35}. This
56 might indirectly suggest the absence of CD74-NRG1 gene alterations in our dataset. Nevertheless,
57
58
59
60
61
62
63
64
65

we acknowledge that gene rearrangements other than ALK were not investigated in this study.

Further analyses are therefore warranted in this direction, since a recent study has identified recurrent gene fusions implicated in the pathogenesis of *KRAS* wild-type mucinous lung ADC¹⁵.

Approximately half of the samples (27/52, 52%) were negative for TTF1 expression. This could indirectly point out at a pivotal role of *NKX2-1* (the gene encoding for TTF1) in tumorigenesis of mucinous pulmonary ADC, as suggested by previous studies^{36,37,38}.

Genotyping of mucinous ADC samples could reveal individual patients who might benefit from targeted therapeutic intervention. We found seven cases carrying *PIK3CA* oncogenic mutations with an overall prevalence of 13% that is higher than the 3% (1/30 cases) reported by Shim and colleagues earlier this year¹⁵. *PIK3CA* status might be used to select patients potentially responsive to PI3K inhibitors in clinical trials^{39,40}. However, all *PIK3CA* mutated tumors co-harbored *KRAS* mutations, which may be detrimental in showing single agent activity of PI3K/AKT/mTOR axis inhibitors⁴¹. Overall, in our study we investigated a highly morphologically selected series of microdissected mucinous ADC cases with a genetic profile which differs from that of conventional ADC: the mutation prevalence and the presence of *TP53* and *PI3KCA* genetic abnormalities could suggest a partial overlap with genetic profile of squamous carcinoma⁴².

Noteworthy, we detected the hotspot IDH1 R132H oncogenic mutation in two samples. IDH1 has been proposed as a plasma biomarker for the diagnosis of lung ADCs⁴³ and the pharmacological inhibition of the mutant enzyme has been shown to block the synthesis of the 'oncometabolite' R-2-hydroxyglutarate, inducing antitumor effects in glioma preclinical models²³. Although clinical studies are still in an early phase, a selective mutant IDH1 inhibitor called AG-120 has recently shown activity in patients affected by IDH1-mutant haematological malignancies⁴⁴. No data are available about the activity of AG-120 in IDH-1 mutant lung cancer patients, but IDH1 mutations have been reported to occur in 1.5% lung ADCs^{8,45}. Nevertheless, in our series, both IDH1 mutated

1
2
3
4
5
6
7
8
9
tumours co-harbored KRAS mutations and showed a high number of mutations, raising caution on
the functional relevance of IDH1 as a driver of tumorigenesis in these particular cases. The
observed *EGFR* mutations occurred outside the “conventional” hot-spots (exons 19 and 21)⁹ that
confer *EGFR*-TK inhibitor sensitivity^{46,47}.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
We report that patients carrying tumors with a higher number of likely somatic non synonymous
alterations might have a better prognosis, even when adjusted by stage of disease. However, this
finding must be interpreted with caution, given the limited number of sequenced genes and the
small number of events available for prognostic analysis. The number of mutations in a cancer
sample can also inform treatment choice. Indeed, a recent study has shown that a higher
nonsynonymous mutation burden in NSCLC is associated with increased neo-antigen formation
and clinical benefit from immunotherapy⁴⁸.

28
29
30
31
32
33
34
35
36
37
38
We acknowledge that our study has sequenced only a small portion of the cancer genome. In
order to draw a more detailed molecular landscape of lung ADC, future studies should incorporate
exome sequencing and transcriptome analysis of a large series of samples to unveil inter-tumoral
(and possibly intra-tumoral) genomic heterogeneity.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
In conclusion, novel somatic mutations were identified in mucinous lung adenocarcinoma and the
mutation frequency of altered genes were correlated with clinical-pathological data. Some of the
identified genes can be tackled by specific targeted therapies. While preclinical studies are needed
to assess the role of these gene alterations as oncogene drivers, the limited therapeutic
performance of cytotoxic chemotherapy in patients with mucinous or colloid ADC represents the
background for pivotal studies to be conducted in tumors harboring one or more of the currently
reported gene alterations.

REFERENCES

1. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244-285.
2. Travis WD, Brambilla E, Burke AP, et al. *Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: IARC Press; 2015.
3. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. *Am J Surg Pathol* 2005;29:633-639.
4. Park WY, Kim MH, Shin DH, et al. Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin. *Mod Pathol* 2012;25:1265-1274.
5. Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. *Lung Cancer* 2014;84:281-288.
6. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol* 2011;24:653-664.
7. Cai D, Li H, Wang R, et al. Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. *Onco Targets Ther* 2014;7:2127-2132.
8. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543-550.
9. Kadota K, Yeh YC, D'Angelo SP, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. *Am J Surg Pathol* 2014;38:1118-1127.

10. Zenali MJ, Weissferdt A, Solis LM, et al. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. *Hum Pathol* 2015;46:836-842.
11. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. *Lung Cancer* 2010;68:185-191.
12. Skoulidis F, Byers LA, Diao L, et al. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. *Cancer Discov* 2015;5:860-877.
13. Zhang Y, Wang R, Li Y, et al. Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas. *J Thorac Oncol* 2015;10:1444-1450.
14. Fernandez-Cuesta L, Plenker D, Osada H, et al. CD74-NRG1 fusions in lung adenocarcinoma. *Cancer Discov* 2014;4:415-422.
15. Shim HS, Kenudson M, Zheng Z, et al. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. *J Thorac Oncol* 2015;10:1156-1162.
16. Edge SB, Byrd DR, Compton CC, et al. *TNM Cancer Staging* New York: Springer; 2009.
17. Ali G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. *Arch Pathol Lab Med* 2014;138:1449-1458.
18. Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. *J Thorac Oncol* 2015;10:492-499.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
19. Kumar A, White TA, MacKenzie AP, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. *Proc Natl Acad Sci U S A* 2011;108:17087-17092.
20. Bourgon R, Lu S, Yan Y, et al. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. *Clin Cancer Res* 2014;20:2080-2091.
21. Choudhary A, Mambo E, Sanford T, et al. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. *BMC Med Genomics* 2014;7:62.
22. Vatrano S, Righi L, Vavalà T, et al. Molecular and histological changes in post-treatment biopsies of non-squamous non-small cell lung cancer: a retrospective study. *Targeted Oncology* 2015 Aug 28 [Epub ahead of print].
23. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* 2013;340:626-630.
24. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. *Mod Pathol* 2011;24:1248-1253.
25. Zhang Y, Sun Y, Xiang J, et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2014;148:1193-1199.
26. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. *J Thorac Oncol* 2011;6:1496-1504.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
27. Kim YK, Shin DH, Kim KB, et al. MUC5AC and MUC5B enhance the characterization of mucinous adenocarcinomas of the lung and predict poor prognosis. *Histopathology* 2015;67:520-528.
28. Yamakawa H, Takayanagi N, Ishiguro T, et al. A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma. *Intern Med* 2013;52:2781-2784.
29. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. *Am J Surg Pathol* 2010;34:1155-1162.
30. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. *Mod Pathol* 2012;25:1117-1127.
31. von der Thusen JH, Tham YS, Pattenden H, et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system. *J Thorac Oncol* 2013;8:37-44.
32. Lee HY, Lee KS, Kwon OJ, et al. Reliability of small biopsy or cytology for the diagnosis of pulmonary mucinous adenocarcinoma. *J Clin Pathol* 2014;67:587-591.
33. Ichinokawa H, Ishii G, Nagai K, et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. *Hum Pathol* 2013;44:2636-2642.
34. Timar J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. *Curr Opin Oncol* 2014;26:138-144.
35. Nakaoku T, Tsuta K, Ichikawa H, et al. Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. *Clin Cancer Res* 2014;20:3087-3093.
36. Winslow MM, Dayton TL, Verhaak RG, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. *Nature* 2011;473:101-104.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
37. Maeda Y, Tsuchiya T, Hao H, et al. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. *J Clin Invest* 2012;122:4388-4400.
 38. Snyder EL, Watanabe H, Magendantz M, et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. *Mol Cell* 2013;50:185-199.
 39. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. *J Clin Oncol* 2012;30:777-782.
 40. Janku F, Hong DS, Fu S, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. *Cell Rep* 2014;6:377-387.
 41. Ganesan P, Janku F, Naing A, et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. *Mol Cancer Ther* 2013;12:2857-2863.
 42. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519-525.
 43. Sun N, Chen Z, Tan F, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. *Clin Cancer Res* 2013;19:5136-5145.
 44. de Botton S, Pollyea SA, Stein EM, et al. Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced, IDH1-mutant hematologic malignancies. 20th Congress of the European Hematology Association. Vienna: 2015: Abstract P563.
 45. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107-1120.
 46. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-1500.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

47. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306-13311.

48. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124-128.

FIGURE LEGENDS

Figure 1. Representative morphological patterns of 54 mucinous ADC (hematoxylin and eosin stains). A) Pure IMA (mucinous features $\geq 90\%$); B) Mixed IMA with up to 50% of non-mucinous ADC component; C) mucinous ADC with abundant extracellular mucin ($\geq 10\%$ of the tumor); D) CPA showing mucous-pools lined by columnar tumor cells; E) Mucinous ADC with tuft growth (insert: high power field of bunches or small clusters of neoplastic mucinous cells attached to the alveolar wall); F) Signet ring cells component (cells with large intracellular mucin drops and peripheral nuclei displaced toward one end of the cytoplasm).

Figure 2. Total of genetic variations in 52 mucinous ADC. A) total genetic variations identified (namely non-sense, non synonymous likely-germinal, non synonymous likely-somatic and synonymous alterations) for each sequenced tumor in exonic or regulatory regions. B) Distribution of nucleotide changes. (Abbreviations: Syn: synonymous; LG: likely germinal; LS: likely somatic)

Figure 3. Distribution of tumor-specific somatic non-synonymous mutations. A) Heatmap of the tumor specific somatic mutations identified for 52 mucinous ADC samples in each gene, clustered according to specific signaling pathways (Abbreviations: *a sample was considered to harbor a complex mutation when an InDel was detected concomitant with point mutations; RTK: Receptor Tyrosine Kinases). B) Histogram of the number of sample for each mutated gene.

Figure 4. Kaplan-Meier survival curves for patients segregated according to the number of non-synonymous likely somatic alterations. Overall survival in tumors with ≥ 2 mutation count (N= 29) compared to tumors with 0-1 mutations (N= 23) (HR 0.21, 95% CI 0.08 to 0.54, log-rank $p < 0.001$).

TABLE 1. Clinical pathological characteristics of 54 primary lung mucinous adenocarcinoma tumor samples.

Parameter	Total #54 (%)	IMA#50 (%)	CPA #4 (%)	IMA #50		p-value
				Pure #32 (%)	Mixed #18 (%)	
Age, mean (range)	65 (41-84)	65 (41-84)	60 (47-78)	64 (41-84)	66 (42-82)	
Sex						
Male	31 (57)	29 (58)	2 (50)	19 (59)	10 (55)	<i>ns</i>
Female	23 (43)	21 (42)	2 (50)	13 (41)	8 (45)	
Smoking habit						
No	12 (22)	12 (24)	0	7 (22)	5 (28)	<i>ns</i>
Yes	42 (78)	38 (76)	4 (100)	25 (78)	13 (72)	
Vascular Invasion						
Yes	6 (11)	6 (12)	0	1 (3)	5 (28)	0.01
No	48 (88)	44 (88)	4 (100)	31 (97)	13 (72)	
Growth Pattern						
Predominant lepidic	45 (83)	41 (82)	4 (100)	32 (100)	9 (50)	< 0.0001
Predominant invasive	9 (17)	9 (18)	0	0	9 (50)	
Extracellular mucin						
Presence	27 (50)	23 (46)	4 (100)	14 (44)	9 (50)	<i>ns</i>
Absence	27 (50)	27 (54)	0	18 (56)	9 (50)	
Tufts						
Presence	46 (85)	43 (86)	3 (75)	30 (94)	13 (72)	<i>ns</i>
Absence	8 (15)	7 (14)	1 (25)	2 (6)	5 (28)	
Signet ring cell features						
Presence	12 (22)	12 (24)	0	7 (22)	5 (28)	0.03
Absence	42 (78)	38 (76)	4 (100)	25 (78)	13 (72)	
pT						
pT1	19 (35)	18 (36)	1 (25)	14 (44)	4 (22)	<i>ns</i>
pT2-3-4	35 (65)	32 (64)	3 (75)	18 (56)	14 (78)	
pN						
pN0	44 (82)	40 (80)	4 (100)	30 (94)	10 (55)	0.001
pN1-2-3	10 (18)	10 (20)	0	2 (6)	8 (45)	
Stage						
I	26 (48)	24 (48)	2 (50)	20 (63)	4 (22)	0.006
II-III-IV	28 (52)	26 (52)	2 (50)	12 (37)	14 (78)	
Status						
Alive	34 (63)	31 (62)	3 (75)	21 (65)	10 (56)	<i>ns</i>
Dead	20 (37)	19 (38)	1 (25)	11 (35)	8 (44)	
Mean OS (months)	61	61	NR	64	34	<i>ns</i>
TTF-1 IHC						
Positive	26 (48)	25 (50)	1 (25)	14 (44)	11 (61)	<i>ns</i>
Negative	28 (52)	25 (50)	3 (75)	18 (56)	7 (39)	

CK7						
<i>Positive</i>	54 (100)	50	4 (100)	32 (100)	18 (100)	-
<i>Negative</i>	0	0	0	0	0	
CDX-2						
<i>Positive</i>	7 (13)	5 (10)	2 (50)	3 (9)	2 (11)	<i>ns</i>
<i>Negative</i>	47 (87)	45 (90)	2 (50)	29 (91)	16 (89)	
CK20						
<i>Positive</i>	26 (48)	25 (50)	1 (25)	18 (56)	7 (39)	<i>ns</i>
<i>Negative</i>	28 (52)	25 (50)	3 (75)	14 (44)	11 (61)	
p53						
<i>Positive</i>	24 (44)	22 (44)	2 (50)	12	10	<i>ns</i>
<i>Negative</i>	30 (55)	28 (56)	2 (50)	20	8	

Abbreviations: IMA: Invasive Mucinous Adenocarcinoma; OS: overall survival, WT: wild type; MUT: mutated.





